Disease relevance of Adenocarcinoma, Clear Cell

• The prevalence of mutations in K-ras gene was 1/8 (13%) in mucinous, 7/29 (24%) in serous, 1/3 (33%) in endometrioid and 2/8 (25%) in clear-cell adenocarcinomas and in H-ras gene 1/8 (13%) in mucinous and 2/29 (7%) in serous adenocarcinomas [1].
• However, strong staining for p53 was noted in each clear cell adenocarcinoma and in none of the nephrogenic adenomas [2].
• Of interest, the clear cell adenocarcinoma revealed DDH overexpression (75%) and mucinous adenocarcinoma revealed low DDH expression (16.7%), although DDH expression did not show any significant variation according to different histotypes [3].
• OBJECTIVE: To evaluate the significance of the expression of HER-2/neu as a prognostic factor, we retrospectively examined its overexpression rates chiefly in ovarian clear cell adenocarcinoma (CCA) and their relationships with FIGO stage, lymph node metastasis, and prognosis [4].
• Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report [5].

High impact information on Adenocarcinoma, Clear Cell

• CONTEXT: The association between in utero exposure to diethylstilbestrol (DES) and clear cell adenocarcinoma (CCA) of the vagina and cervix is well known, yet there has been no systematic study of DES-exposed daughters to determine whether they have an increased risk of other cancers [6].
• The altered mitogen response should be a stimulus for a detailed analysis of the immune system in women exposed to DES during fetal life, some of whom develop later in life clear cell adenocarcinoma of the uterine cervix and vagina [7].
• Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets [8].
• For comparison, eight clear-cell adenocarcinomas with fetal lung features were also examined. beta-Catenin gene mutations were found in all three WDFAs, two BPBs, and none of the clear-cell adenocarcinomas with fetal lung features [9].
• Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells [10].

Chemical compound and disease context of Adenocarcinoma, Clear Cell

• These cancers were found in older women and were more advanced than the clear-cell adenocarcinoma associated with DES [11].
• RESULTS: The mean fractal dimensions of the surface of intracystic solid components in serous, mucinous, endometrioid, and clear cell adenocarcinoma were 1.259, 1.243, 1.238, and 1.182, respectively [12].
• Remarkable suppressive effect of consecutive low-dose cisplatin therapy on advanced ovarian clear cell adenocarcinoma [13].
• Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells [14].
• The levels of superoxide anion production, cytochrome P450, ornithine decarboxylase(E.C.4.1.1.17), catalase(E.C.1.11.1.6), deoxyribonucleic acid, ribonucleic acid and protein have been studied in human kidney and renal clear-cell adenocarcinoma tissues [15].

Biological context of Adenocarcinoma, Clear Cell

• Bcl-2 protein expression associated with resistance to apoptosis in clear cell adenocarcinomas of the vagina and cervix expressing wild-type p53 [16].
• WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma [17].
• Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero [18].
• CONCLUSIONS: The current study shows that CpG hypermethylation is an important mechanism of WT1 and WT1-AS gene inactivation in ovarian clear cell adenocarcinoma [17].
• MT membrane potential (delta psi m) semi-quantitatively assessed by rhodamin 123 (Rh) sensitivity was significantly elevated in acquired Pt-resistant 2008/C13*5.25 cells (C13) established from its parental 2008 cells or known intrinsic Pt-resistant JHOC cells established from ovarian clear cell adenocarcinoma [19].

Anatomical context of Adenocarcinoma, Clear Cell

• Establishment and characterization of cell line SFCC from clear cell adenocarcinoma of the uterine cervix [20].
• CA6 is also expressed by the majority of ovarian endometrioid adenocarcinomas and Brenner tumors and by the majority of endometrioid adenocarcinomas, mucinous adenocarcinomas, and clear cell adenocarcinomas of the endometrium [21].
• Conservative surgery plus adjuvant therapy for vulvovaginal rhabdomyosarcoma, diethylstilbestrol clear cell adenocarcinoma of the vagina, and unilateral germ cell tumors of the ovary [22].

Gene context of Adenocarcinoma, Clear Cell

• PTEN expression in clear cell adenocarcinoma of the ovary [23].
• Expression of the MUC1 gene and sialyl Lewis X was characteristic to all five cell lines derived from clear cell adenocarcinomas [24].
• In contrast, none of 16 clear cell adenocarcinomas showed positive p53 staining [25].
• Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary [26].
• MDR-1 expression was observed in 12.9% of the tumors tested and was more frequently detected in clear cell adenocarcinomas than other histologic subtypes of tumor (10/ 16 vs. 2 / 77, P < 0.001) [25].

References